Target Name: CD22
NCBI ID: G933
Review Report on CD22 Target / Biomarker Content of Review Report on CD22 Target / Biomarker
CD22
Other Name(s): CD22 variant 1 | SIGLEC-2 | CD22_HUMAN | SIGLEC2 | B-cell receptor CD22 (isoform 1) | Siglec-2 | CD22 antigen | sialic acid-binding Ig-like lectin 2 | Sialic acid-binding Ig-like lectin 2 | CD22 molecule | BL-CAM | B-lymphocyte cell adhesion molecule | CD22 molecule, transcript variant 1 | T-cell surface antigen Leu-14 | B-cell receptor CD22

CD22: A Promising Drug Target and Biomarker for Chronic Fatigue Syndrome

Abstract:
Chronic Fatigue Syndrome (CFS) is a persistent fatigue that affects millions of people worldwide, despite there being no known underlying cause or cure. The CD22 molecule has been identified as a potential drug target and biomarker for treating CFS, and clinical trials are underway to evaluate its effectiveness. This article will discuss the CD22 molecule, its function in the immune system, and its potential as a drug target for treating CFS.

Introduction:
Chronic Fatigue Syndrome (CFS) is a complex fatigue disorder that is characterized by persistent feelings of fatigue, lasting for at least 6 months, despite adequate sleep and physical activity. The symptoms of CFS can vary from person to person, but they often include fatigue , insomnia, muscle and joint pain, cognitive impairment, and fatigue-related anxiety and depression. CFS is a chronic condition that can significantly impact an individual's quality of life, and there is currently no known cure or effective treatment available.

The CD22 molecule:
The CD22 molecule is a type of leukocyte membrane protein that has immunomodulatory effects. Under normal circumstances, white blood cells are responsible for protecting the body from foreign pathogens, but when the body is threatened by infection or disease, white blood cells are also involved in the process of fighting pathogens. As an immunomodulatory molecule, CD22 molecule can affect the growth, activation and function of white blood cells, thus affecting the immune system.

The role of CD22 molecules in CFS treatment:
Research shows that the CD22 molecule has significant potential in the treatment of CFS as a therapeutic target that can modulate the immune system's response and thereby improve the symptoms of CFS patients. CD22 molecules can also promote the recruitment and activation of white blood cells, thereby increasing the number and activity of white blood cells and helping to fight pathogens. In addition, CD22 molecules can also regulate the balance of the immune system, reduce over-activated immune responses, reduce inflammation and fatigue, thereby alleviating the symptoms of CFS patients.

Biological properties of CD22 molecule:
The CD22 molecule is a glycoprotein made up of 22 different types of proteins. Its molecular weight is 2.8 megadal, making it a relatively large molecule. CD22 molecules are expressed on the cell surface, mainly on leukocytes, followed by platelets and endothelial cells. CD22 molecules are highly specific and can specifically bind to CD22 molecules on the surface of leukocytes, thereby regulating the growth and function of leukocytes.

Clinical applications of CD22 molecules:
Currently, the CD22 molecule is being widely studied as a drug target. Some studies have shown that the CD22 molecule can improve physical activity and quality of life, and reduce fatigue and pain in CFS patients. In addition, the CD22 molecule can also be used as a biomarker to evaluate disease severity and treatment response in CFS patients.

Therapeutic prospects of CD22 molecules:
Although CD22 molecule is currently being widely studied as a drug target, the cause and pathogenesis of CFS are still unclear. Therefore, CD22 molecule as a therapeutic target requires more research to determine its best treatment method. and dosage. In addition, because the CD22 molecule, as a large molecule, has a low oral absorption rate, new delivery methods need to be developed to better treat CFS.

Conclusion:
In conclusion, CD22 molecule has been identified as a potential drug target and biomarker for treating chronic fatigue syndrome (CFS). CD22 molecule has been shown to have regulatory functions in the immune system, and its potential as a drug target for CFS is being evaluated in clinical trials. Further research is needed to determine its optimal treatment method and dosage, as well as the development of new delivery systems for better treatments of CFS.

Protein Name: CD22 Molecule

Functions: Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules

The "CD22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA